All Brands Owned by Jazz Pharmaceuticals
Jazz Pharmaceuticals owns 1 brand in our database. Browse the complete portfolio of Jazz Pharmaceuticals subsidiaries and brands across various industries.
Company Type
public
Headquarters
Dublin, Ireland
Brand Portfolio
1 brands
Stock
Nasdaq: JAZZ
Filter by Category
Complete Brand Portfolio
About Jazz Pharmaceuticals
What does Jazz Pharmaceuticals make?
Jazz Pharmaceuticals makes prescription therapies in neuroscience and oncology. Key products include Xywav and Xyrem for sleep disorders, Epidiolex for epilepsy, Rylaze for leukemia, Zepzelca for lung cancer, and Defitelio for hepatic veno-occlusive disease.
Is Jazz Pharmaceuticals publicly traded?
Yes, Jazz Pharmaceuticals plc is publicly traded on Nasdaq under the ticker symbol JAZZ. The company is incorporated in Ireland and headquartered in Dublin.
Who founded Jazz Pharmaceuticals?
Jazz Pharmaceuticals was founded in 2005 by Bruce Cozadd, who previously served as Executive Vice President and Chief Operating Officer at ALZA Corporation. Cozadd continues to serve as Chairman and CEO.
Where is Jazz Pharmaceuticals headquartered?
Jazz Pharmaceuticals is headquartered in Dublin, Ireland. The company maintains major operational hubs in Palo Alto, California and Philadelphia, Pennsylvania, with additional offices in Europe and Canada.
How many employees does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals employed approximately 2,890 people as of December 31, 2025. The company's workforce is distributed across research and development, manufacturing, and commercial operations.
Who owns Jazz Pharmaceuticals?
Jazz Pharmaceuticals plc is publicly traded on Nasdaq under the ticker JAZZ. The company has a broad institutional shareholder base with no single controlling shareholder. Bruce Cozadd serves as Chairman and CEO.
Stock Information
Competitors to Jazz Pharmaceuticals
No competing brands found in the same categories. This could be because Jazz Pharmaceuticalsoperates in unique market segments or we're still building our competitor database.
Jazz Pharmaceuticals Brand Portfolio Overview
Jazz Pharmaceuticals maintains a diverse portfolio of 1 brands across multiple industries. This comprehensive brand portfolio demonstrates the company's market presence and strategic business units.
Brand Portfolio by Industry:
- Healthcare & Pharmaceuticals: 1 brands
For consumers and researchers interested in corporate ownership structures, understanding which brands are owned by Jazz Pharmaceuticalsprovides valuable insights into market dynamics, product relationships, and corporate strategy.
Explore More
Jobs at Jazz Pharmaceuticals
Latest News About Jazz Pharmaceuticals
Articles About Jazz Pharmaceuticals
View more articles
Monthly IPO Roundup: August 2026 — July's Biggest Listings
July 2026 IPOs: CXMT raised $8.6B in China's biggest semiconductor IPO ever, Jersey Mike's priced a $1B NYSE debut, Csquare raised $1.05B for data centers, Reformation went public at $886M, and Scribe Therapeutics became the first gene editing IPO in two years. Full recap.
Monthly M&A Roundup: July 2026 Brand Ownership Changes
July 2026's biggest deals: Stripe and Advent bid $53B for PayPal, Vertex acquired Crinetics for $10B, Couche-Tard bought Żabka for $8.6B, Utz went private in a $2.9B deal with Intersnack, and Kroger acquired Giant Eagle for $1.65B. Full breakdown.
Monthly IPO Roundup: July 2026 — June's Biggest Listings
June 2026 was the most historic IPO month in market history: SpaceX priced at $135 per share on June 12, raising $75 billion in the largest IPO ever. Quantinuum raised $1.68B, INNIO priced a $2.8B deal, and Bending Spoons filed for a $20B Nasdaq listing. Full recap.